When you think about it, spending on phase I-IV services by pharma sponsors is roughly equivalent to revenue generated by CROs. One company’s expense is another company’s revenue. ISR wanted to see how the largest public CROs stacked up to the largest pharma companies in terms of their phase I-IV activities. - See more at: http://www.isrreports.com/free-resources/clinical-development-activity-perspective/#sthash.7xWDch7f.dpuf

1. Pharma
CRO
A head-to-head comparison of
Pharma and CRO phase I-IV activities.
Rank Company Total R&D Development Phase I-IV
1 Novartis $9,727 $6,128 $4,351
2 Roche $9,656 $6,083 $4,319
3 Merck $7,123 $4,487 $3,186
4 Pfizer $6,641 $4,184 $2,971
5 Quintiles $2,920
6 Sanofi $6,420 $4,045 $2,872
7 GSK $5,683 $3,580 $2,542
8 Eli Lilly $5,531 $3,485 $2,474
9 Bayer $4,313 $2,717 $1,929
10 AZ $4,281 $2,697 $1,915
11 Amgen $4,083 $2,572 $1,826
12 BMS $3,715 $2,340 $1,662
13 PAREXEL $1,532
14 Covance $1,494
15 Takeda $3,277 $2,065 $1,466
16 ICON $1,336
17 Otsuka $2,379 $1,499 $1,064
18 Gilead $2,167 $1,365 $969
19 Novo Nordisk $2,120 $1,336 $948
20 Astellas $1,998 $1,259 $894
Methodology
When you think about it, spending on phase I-IV services by pharma sponsors is
roughly equivalent to revenue generated by CROs. One company’s expense is
another company’s revenue. ISR wanted to see how the largest public CROs stacked
up to the largest pharma companies in terms of their phase I-IV activities. ISR used
the assumptions we generated in developing our 2014 CRO Market Size report to
develop a side-by-side comparison of phase I-IV activity between sponsors and
CROs. For sponsors: We took their annual R&D spending, multiplied it by 63% to get
their development spending, then multiplied that by 71% to get their phase I-IV
spending. For CROs: We took just their clinical development revenue (not commer-
cial, consulting, preclinical). Is this an exact match, no. However, directionally we find
that of the 20 companies performing the most phase I-IV activities, at least four of
them are CROs and, if their financials were publicly available, we could have easily
included PPD and perhaps PRA, inVentiv Health Clinical, and INC Research in the list.
www.ISRreports.com info@ISRreports.com
Clinical
development
activity in
perspective
(Annual $B USD)